erythrosine and razoxane

erythrosine has been researched along with razoxane in 5 studies

Research

Studies (5)

TimeframeStudies, this research(%)All Research%
pre-19900 (0.00)18.7374
1990's1 (20.00)18.2507
2000's3 (60.00)29.6817
2010's1 (20.00)24.3611
2020's0 (0.00)2.80

Authors

AuthorsStudies
Boehme, P; Gordeuk, VR; John, C; Loyevsky, M; Sacci, JB; Weglicki, W1
Barnabé, N; Hasinoff, BB; Venkataram, S; Zastre, JA1
Hasinoff, BB1
Hasinoff, BB; Schroeder, PE1
Draenert, GF; Huetzen, DO; Kämmerer, PW; Nacu, V; Palarie, V; Wagner, W1

Other Studies

5 other study(ies) available for erythrosine and razoxane

ArticleYear
Plasmodium falciparum and Plasmodium yoelii: effect of the iron chelation prodrug dexrazoxane on in vitro cultures.
    Experimental parasitology, 1999, Volume: 91, Issue:2

    Topics: Animals; Cells, Cultured; Chromatography, High Pressure Liquid; Deferoxamine; Erythrocytes; Ethylenediamines; Ferrous Compounds; Fluoresceins; Fluorescent Dyes; Glycine; Humans; Iron Chelating Agents; Liver; Malaria, Falciparum; Mice; Microscopy, Fluorescence; Parasitemia; Plasmodium falciparum; Plasmodium yoelii; Prodrugs; Quaternary Ammonium Compounds; Razoxane; Spectrometry, Fluorescence; Surface Properties

1999
Deferiprone protects against doxorubicin-induced myocyte cytotoxicity.
    Free radical biology & medicine, 2002, Jul-15, Volume: 33, Issue:2

    Topics: Animals; Animals, Newborn; Antineoplastic Agents; Cell Survival; Cells, Cultured; Deferiprone; Doxorubicin; Electron Spin Resonance Spectroscopy; Fluoresceins; Free Radicals; Indicators and Reagents; Iron; Iron Chelating Agents; L-Lactate Dehydrogenase; Myocytes, Cardiac; Oxidation-Reduction; Pyridones; Rats; Rats, Sprague-Dawley; Razoxane

2002
Dexrazoxane (ICRF-187) protects cardiac myocytes against hypoxia-reoxygenation damage.
    Cardiovascular toxicology, 2002, Volume: 2, Issue:2

    Topics: Animals; Cardiovascular Agents; Disease Models, Animal; Dose-Response Relationship, Drug; Ethylenediamines; Extracorporeal Membrane Oxygenation; Fluoresceins; Fluorescent Dyes; Glycine; Hypoxia; Ion Transport; L-Lactate Dehydrogenase; Models, Cardiovascular; Myocytes, Cardiac; Rats; Rats, Sprague-Dawley; Razoxane; Time Factors; Treatment Failure

2002
The doxorubicin-cardioprotective drug dexrazoxane undergoes metabolism in the rat to its metal ion-chelating form ADR-925.
    Cancer chemotherapy and pharmacology, 2002, Volume: 50, Issue:6

    Topics: Animals; Biotransformation; Cardiovascular Agents; Chelating Agents; Chromatography, High Pressure Liquid; Ethylenediamines; Fluoresceins; Glycine; Half-Life; Indicators and Reagents; Infusions, Intravenous; Iron; Male; Molecular Structure; Rats; Rats, Sprague-Dawley; Razoxane

2002
Dexrazoxane shows cytoprotective effects in zoledronic acid-treated human cells in vitro and in the rabbit tibia model in vivo.
    Journal of cranio-maxillo-facial surgery : official publication of the European Association for Cranio-Maxillo-Facial Surgery, 2012, Volume: 40, Issue:8

    Topics: Animals; Apoptosis; Bone Density Conservation Agents; Bone Resorption; Cell Culture Techniques; Cell Line; Cell Shape; Cell Survival; Collagen; Coloring Agents; Cytoprotection; Diphosphonates; Drug Carriers; Durapatite; Female; Fibroblasts; Fluoresceins; Fluorescent Dyes; Gingiva; Humans; Imidazoles; Models, Animal; Osteoblasts; Osteogenesis; Protective Agents; Rabbits; Razoxane; Tetrazolium Salts; Thiazoles; Tibia; Zoledronic Acid

2012